{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T04:37:37Z","timestamp":1783312657844,"version":"3.54.6"},"reference-count":19,"publisher":"Wiley","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81470649"],"award-info":[{"award-number":["81470649"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Ophthalmology"],"published-print":{"date-parts":[[2017]]},"abstract":"<jats:p><jats:italic>Objective<\/jats:italic>. To determine the prevalence and risk factors for the recurrence of retinopathy of prematurity (ROP) in Zone II Stage 3+ after ranibizumab treatment.<jats:italic>Methods<\/jats:italic>. This was a retrospective, nonrandomized, noncontrolled study that excluded Zone I and aggressive posterior ROP (APROP) cases. Infants who developed Zone II Stage 3 ROP with plus disease and underwent initial intravitreal injection of ranibizumab (IVR) were recruited. Patients were divided into 2 groups based on the outcome after initial ranibizumab treatment: recurrence of ROP or favorable outcome. Data was collected and analyzed by SPSS 16.0.<jats:italic>Results<\/jats:italic>. Forty-two patients were included, and 80 eyes with Zone II Stage 3+ were subjected to IVR treatment. Eleven of 42 patients (26.2%, 18 eyes) had a recurrence of ROP after the initial treatment. On univariate analysis, preretinal hemorrhage before treatment was significantly different between the two groups (<mml:math xmlns:mml=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M1\"><mml:mi>P<\/mml:mi><mml:mo>=<\/mml:mo><mml:mn>0.000<\/mml:mn><\/mml:math>). Multivariate analysis found that preretinal hemorrhage before treatment was the only factor associated with the recurrence of ROP in our study (<mml:math xmlns:mml=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M2\"><mml:mi>P<\/mml:mi><mml:mo>=<\/mml:mo><mml:mn>0.004<\/mml:mn><\/mml:math>).<jats:italic>Conclusions<\/jats:italic>. The recurrence rate of ROP in Zone II Stage 3+ after initial ranibizumab treatment was notable and preretinal hemorrhage before treatment was associated with the recurrence of ROP in our study.<\/jats:p>","DOI":"10.1155\/2017\/5078565","type":"journal-article","created":{"date-parts":[[2017,4,9]],"date-time":"2017-04-09T17:01:33Z","timestamp":1491757293000},"page":"1-5","source":"Crossref","is-referenced-by-count":25,"title":["Recurrence of Retinopathy of Prematurity in Zone II Stage 3+ after Ranibizumab Treatment: A Retrospective Study"],"prefix":"10.1155","volume":"2017","author":[{"given":"Qinrui","family":"Hu","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Peking University People\u2019s Hospital, Beijing Key Laboratory for the Diagnosis and Treatment of Retinal and Choroid Diseases, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujing","family":"Bai","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Peking University People\u2019s Hospital, Beijing Key Laboratory for the Diagnosis and Treatment of Retinal and Choroid Diseases, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8020-5513","authenticated-orcid":true,"given":"Xiaoli","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Peking University People\u2019s Hospital, Beijing Key Laboratory for the Diagnosis and Treatment of Retinal and Choroid Diseases, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lvzhen","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Peking University People\u2019s Hospital, Beijing Key Laboratory for the Diagnosis and Treatment of Retinal and Choroid Diseases, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3054-0839","authenticated-orcid":true,"given":"Yi","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, China-Japan Friendship Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5161-9458","authenticated-orcid":true,"given":"Xiaoxin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Peking University People\u2019s Hospital, Beijing Key Laboratory for the Diagnosis and Treatment of Retinal and Choroid Diseases, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","reference":[{"key":"1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e318275394a"},{"key":"2","doi-asserted-by":"publisher","DOI":"10.1016\/j.earlhumdev.2009.08.026"},{"key":"3","doi-asserted-by":"publisher","DOI":"10.3980\/j.issn.2222-3959.2013.02.23"},{"key":"4","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000000380"},{"key":"5","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e31817f2f15"},{"key":"6","doi-asserted-by":"publisher","DOI":"10.1097\/APO.0000000000000039"},{"key":"7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1007374"},{"key":"8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2011.04.028"},{"key":"9","doi-asserted-by":"publisher","DOI":"10.3109\/14767058.2011.587056"},{"key":"10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2012.07.012"},{"key":"11","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-015-0001-7"},{"issue":"3","key":"12","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.ophtha.2016.10.032","volume":"124","year":"2017","journal-title":"Ophthalmology"},{"key":"13","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000000578"},{"key":"14","doi-asserted-by":"publisher","DOI":"10.5935\/0004-2749.20150090"},{"key":"15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-3768.2012.02469.x"},{"key":"16","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.84.6.596"},{"key":"17","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(14)70278-8"},{"key":"18","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9394(84)90382-9"},{"key":"19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.06.055"}],"container-title":["Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/joph\/2017\/5078565.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/joph\/2017\/5078565.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/joph\/2017\/5078565.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T10:31:16Z","timestamp":1498386676000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.hindawi.com\/journals\/joph\/2017\/5078565\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":19,"alternative-id":["5078565","5078565"],"URL":"https:\/\/doi.org\/10.1155\/2017\/5078565","relation":{},"ISSN":["2090-004X","2090-0058"],"issn-type":[{"value":"2090-004X","type":"print"},{"value":"2090-0058","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}